Skip to main content

Azora Therapeutics, Inc.

corporate_fare Company Profile

Azora Therapeutics, Inc.

ADIL·NASDAQ·Life Sciences·CIK 0001513525

We are a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. Our primary investigational drug candidate, AD04, is being developed to treat alcohol use disorder (AUD). AD04 was studied in a Phase 3 clinical trial, called the ONWARD trial, for AUD in patients with specific genetic profiles identified using our companion diagnostic genetic test. We are now concentrating on completing the clinical development program for AD04 in these genetic subgroups to meet regulatory requirements, primarily in the US and secondarily in Europe/UK. The vast majority of our resources have been dedicated to AD04's development, including preparing for and conducting clinical trials, providing general and administrative support, and protecting our intellectual property. We anticipate these activities will continue to require most of our resources. We do not currently have any products approved for sale and have not generated significant revenue since our inception. Our operations have been funded primarily through private and public placements of debt, equity securities, and an equity line. Our current cash and cash equivalents are not expected to fund operations for the twelve months from the date of filing this Annual Report on Form 10-K. We have incurred net losses every year since inception, including approximately $8.0 million for the year ended December 31, 2025, and $13.2 million for the year ended December 31, 2024. Our accumulated deficits were approximately $90.0 million as of December 31, 2025, and $82.0 million as of December 31, 2024.

Azora Therapeutics, Inc. (NASDAQ:ADIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for ADIL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ADIL spans 8-K, 10-Q, 10-Q/A, DEFA14A.

Recent high-impact activity:

  • Azora Posts $64.6M Q3 Loss on $57.1M Non-Cash Warrant Charge; Going Concern Stands
  • Azora 10-Q: $22.0M Cash, Going-Concern Doubt, Material Weakness Disclosed
  • Azora Replaces Entire Board and Converts 9.9M Preferred Shares Into Common
  • Adial Becomes Azora Therapeutics, Swaps Ticker to AZR With New CEO and $32M in Tow
  • Adial Becomes Azora Therapeutics; New CEO and CFO Named; Authorized Shares Raised to 500M

Dilution Risk

Low risk

Filing-implied dilution signals for ADIL, detected from its recent SEC filings.

1 shelf registration

Resale Registration Amended · No Company Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$4.86
Market cap
$13.26M
Volume
99.7K (2.6× avg)
3-mo avg 38.6K
Last traded · 2026-10-29

show_chartPrice Chart

Loading chart...

feed ADIL - Latest Insights

ADIL
Nov 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info
ADIL
Oct 20, 2026, 8:25 PM EDT
Filing Type: 10-Q/A
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.86 info
Change: +$1.07 (+28%) info
Market Cap: $13.261M info
ADIL
Sep 18, 2026, 5:18 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Sep 18, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Sep 16, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.24
Real-time Price: $4.86 info
Change: -$0.380 (-7%) info
Market Cap: $13.261M info
ADIL
Aug 28, 2026, 4:49 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $5.60
Real-time Price: $4.86 info
Change: -$0.740 (-13%) info
Market Cap: $13.261M info
ADIL
Aug 24, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $5.40
Real-time Price: $4.86 info
Change: -$0.540 (-10%) info
Market Cap: $13.261M info
ADIL
Aug 21, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.00
Real-time Price: $4.86 info
Change: -$1.14 (-19%) info
Market Cap: $13.261M info
ADIL
Aug 17, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.08
Real-time Price: $4.86 info
Change: +$1.78 (+58%) info
Market Cap: $13.261M info
ADIL
Aug 17, 2026, 7:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.08
Real-time Price: $4.86 info
Change: +$1.78 (+58%) info
Market Cap: $13.261M info
ADIL
Aug 14, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.98
Real-time Price: $4.86 info
Change: +$0.880 (+22%) info
Market Cap: $13.261M info
ADIL
Aug 13, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.20
Real-time Price: $4.86 info
Change: +$0.660 (+16%) info
Market Cap: $13.261M info
ADIL
Aug 10, 2026, 9:17 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $4.21
Real-time Price: $4.86 info
Change: +$0.650 (+15%) info
Market Cap: $13.261M info
ADIL
Aug 10, 2026, 9:13 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $4.86 info
Change: +$0.650 (+15%) info
Market Cap: $13.261M info
ADIL
Jul 01, 2026, 10:30 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $4.86 info
Change: +$2.27 (+87%) info
Market Cap: $13.261M info
ADIL
Jun 16, 2026, 6:14 AM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.70
Real-time Price: $4.86 info
Change: +$2.16 (+80%) info
Market Cap: $13.261M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets